Education
About Us
Working with TipRanks
Follow Us
Cuorips Inc. (JP:4894)
:4894
Top Page
Cuorips Inc.
(4894)
Rating:33Underperform
Price Target:―
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥49.24B
Dividend YieldN/A
Average Volume (3M)134.23K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth-12.82%
EPS Growth-19.87%
CountryJP
Employees59
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.94
Shares Outstanding8,222,966
10 Day Avg. Volume117,170
30 Day Avg. Volume134,230
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cuorips Inc. Business Overview & Revenue Model
Company DescriptionCuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyCuorips Inc. generates revenue through the development and commercialization of regenerative medicine products targeting cardiac diseases. The company makes money by licensing its proprietary technologies and therapies to pharmaceutical and biotechnology companies. Additionally, Cuorips Inc. may receive funding through collaborative research agreements and partnerships with healthcare institutions and academic entities. Revenue streams could also include milestone payments and royalties from successfully developed and marketed therapies. The company's earnings are significantly influenced by its ability to advance its pipeline products through clinical trials and secure regulatory approvals.
Cuorips Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 23.10M | 38.28M | 13.91M | 220.00K |
| Gross Profit | 9.63M | 21.01M | 10.65M | 138.00K |
| EBITDA | -518.00M | -371.78M | -280.40M | -221.17M |
| Net Income | -632.18M | -452.08M | -375.34M | -307.83M |
Balance Sheet | ||||
| Total Assets | 6.18B | 3.59B | 4.04B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 5.58B | 2.94B | 3.34B | 3.54B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 200.96M | 133.79M | 149.36M | 141.95M |
| Stockholders Equity | 5.98B | 3.45B | 3.90B | 4.22B |
Cash Flow | ||||
| Free Cash Flow | -487.01M | -412.18M | -249.45M | -950.97M |
| Operating Cash Flow | -451.06M | -401.61M | -220.76M | -282.80M |
| Investing Cash Flow | -35.00M | -8.97M | -28.44M | -670.21M |
| Financing Cash Flow | 3.13B | 10.69M | 48.54M | 3.77B |
Cuorips Inc. Technical Analysis
Negative
6000.00
Price Trends
6096.20
Negative
6639.10
Negative
6322.95
Negative
Market Momentum
-6.11
Negative
49.14
Neutral
60.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Negative. The current price of 6000 is above the 20-day moving average (MA) of 5909.00, below the 50-day MA of 6096.20, and below the 200-day MA of 6322.95, indicating a neutral trend. The MACD of -6.11 indicates Negative momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 60.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4894.
Cuorips Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ¥347.74B | 11.06 | -2.99% | 2.56% | 11.77% | -10.16% | |
58 Neutral | ¥25.87B | ― | ― | -2.34% | -278.32% | ||
51 Neutral | ¥36.42B | 321.08 | ― | -27.27% | ― | ||
51 Neutral | ¥76.61B | ― | ― | 374.19% | 35.53% | ||
47 Neutral | ¥18.70B | ― | ― | -100.00% | -1079.89% | ||
33 Underperform | ¥49.24B | ― | ― | -12.82% | -19.87% | ||
32 Underperform | ¥19.79B | ― | ― | ― | -9.65% |
* Healthcare Sector Average
Performance Comparison
JP:4894
Cuorips Inc.
6,000.00
-1,400.00
-18.92%
JP:4575
CanBas Co., Ltd.
1,004.00
374.00
59.37%
JP:4593
Healios KK
700.00
515.00
278.38%
JP:4599
StemRIM Inc.
301.00
-154.00
-33.85%
JP:4889
Renascience Inc.
2,865.00
2,510.00
707.04%
JP:7774
Japan Tissue Engineering Co., Ltd.
637.00
-55.00
-7.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.